On-Demand Webinar
Understanding the patient journey—from diagnosis through treatment—is crucial for drug developers aiming to create more effective therapies. Using non small cell lung cancer (NSCLC) as an example, PurpleLab and Genentech will explore how to leverage RWD to eliminate blind spots in the patient journey — informing every phase of a drug’s lifecycle, from clinical development to market access.
The webinar will include executives from PurpleLab and Dr. Ben Freiberg, Principal Informatics Systems Lead with Genentech’s gCS Computational Catalysts. Genentech is owned by Roche.
Among the talking points the webinar will cover are:
- How can RWD be leveraged by pharma companies for the NSCLC patient journey?
- What does the “typical” patient journey for NSCLC look like?
- Mapping the nuanced parts of a patient’s journey
- The value of leveraging Social Determinants of Health data
- Addressing socioeconomic barriers that may hinder clinical trial participation
- Using RWD to improve clinical trial recruitment, clinical endpoints, and inform market access strategies
